Investigational drug · Phase 3
GSK5784283
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
9
Any phase or sponsor naming "GSK5784283"
First trial start
2025
Feb 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK5784283", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Disease, Chronic Obstructive
- Asthma
- Nasal Polyps
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK5784283" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780669 · 624 participants (planned) · Start Aug 27, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Doral, Florida; Derby, Kansas; Lake Charles, Louisiana · 11 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780656 · 624 participants (planned) · Start Sep 11, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Cape Coral, Florida; Greenacres City, Florida; Miami, Florida · 9 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780643 · 514 participants (planned) · Start Aug 27, 2026 · Primary completion Feb 15, 2029
Drug: GSK5784283; Placebo and 1 more · For: Asthma
Sites: Miami Lakes, Florida
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07782996 · 370 participants (planned) · Start Aug 27, 2026 · Primary completion May 4, 2029
Drug: GSK5784283; Placebo and 1 more · For: Asthma
Sites: San Diego, California; Miami, Florida; Miami Lakes, Florida · 13 sites in all
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06748053 · 307 participants · Start Feb 10, 2025 · Primary completion Jul 14, 2026
Drug: GSK5784283; Placebo · For: Asthma
Sites: Little Rock, Arkansas; Long Beach, California; Los Angeles, California · 137 sites in all
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07915791 · 279 participants (planned) · Start Oct 29, 2026 · Primary completion Mar 7, 2029
Drug: GSK3862995B; GSK5784283 and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Newport Beach, California; Miami, Florida; Derby, Kansas · 10 sites in all
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07782970 · 218 participants (planned) · Start Sep 28, 2026 · Primary completion Mar 6, 2029
Drug: GSK5784283; Placebo and 1 more · For: Nasal Polyps
Sites: Tucson, Arizona; Los Angeles, California; Louisville, Kentucky · 9 sites in all
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07782957 · 218 participants (planned) · Start Sep 3, 2026 · Primary completion Mar 6, 2029
Drug: GSK5784283; Placebo and 1 more · For: Nasal Polyps
Sites: Sherman Oaks, California; Wheat Ridge, Colorado; Palm Springs, Florida · 7 sites in all
- A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283Active, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07712393 · 24 participants · Start Jul 17, 2026 · Primary completion Apr 13, 2027
Drug: GSK5784283 · For: Asthma
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pulmonary Disease, Chronic Obstructive
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- TQC3721 forPhase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive
- GSK3862995BPhase 22 trials
GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive
- TQC3721Phase 21 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.